Nalaganje...
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
Ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL). This drug irreversibly inhibits Bruton tyrosine kinase (BTK) by covalently binding to the C481 residue in the BTK kinase domain. BTK is a pivotal protein for B cell receptor signaling and tissue homing of CLL cells. Pr...
Shranjeno v:
| izdano v: | Blood Cancer J |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group UK
2021
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8085243/ https://ncbi.nlm.nih.gov/pubmed/33927183 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-021-00467-7 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|